Nonagon Enables Clinical-Grade Remote Examinations for Heart, Lungs, Abdomen, and More, Potentially Improving Health Outcomes and Reducing Hospital Visits

CAESAREA, ISRAEL, April 19, 2023/EINPresswire.com/ — Nonagon, a fast-growing medical device company based in Israel and the US, has received FDA clearance to sell its N9+ device as an over-the-counter product, making remote patient examinations more accessible than ever. The Nonagon N9+ device allows for clinical-grade remote examinations of various health parameters, including the heart, lungs, abdomen, oxygen saturation, ears, mouth/throat, skin, and body temperature, and automatically documents and shares exam results with physicians via telehealth, potentially contributing to better patient care and outcomes.

“We are thrilled to receive FDA clearance for the Nonagon N9+ device, which brings us one step closer to our mission of making remote digital medicine clinically reliable and accessible to the community,” said Alon Natanson², CEO of Nonagon. “This clearance allows us to offer a cutting-edge solution that empowers patients to proactively manage their health and enhances the capabilities of healthcare providers to remotely monitor and diagnose patients.”

The Nonagon N9+ device will soon be available on the company’s website in June, with plans to launch it in broader distribution shortly thereafter.

With its user-friendly interface and advanced features, the Nonagon N9+ device is poised to revolutionize the healthcare industry by reducing unnecessary in-person visits and possibly improving health outcomes. The device has the potential to greatly benefit patients.

Omer Maman
Nonagon

The post Nonagon Receives FDA Clearance for Over-the-Counter Remote Examination Platform, Making Healthcare More Accessible appeared first on mTelehealth.

JACKSON, MI – AUGUST 10, 2022

With the mission to strengthen its healthcare services for patients and residents, Vista Grande Villa officially announced the adoption of a game-changing digital telehealth platform, Nonagon, to provide its skilled nursing center with 24/7 access to patients’ health care providers (HCPs) whenever the need arises. Nonagon’s N9 hand-held device enables 9 medical-grade exams to be captured and shared with HCPs, bolstered by Nonagon’s proprietary, HIPAA-compliant, and secure communication platform and database.

The FDA-cleared N9 device communicates with a laptop, tablet, or smartphone for clinical-grade remote examinations of the heart, lungs, abdomen, oxygen saturation (important for diagnosing COVID), ears, mouth/throat, skin, and body temperature. Nonagon automatically documents and shares exam results (via photo, audio, video, or text-based message) to physicians which can help in improving health outcomes, reducing visits to the Emergency Room and reducing readmissions.

The integration of Nonagon into Vista Grande Villa’s skilled nursing center’s infrastructure, provided by mTelehealth, comes as part of a grant awarded to Vista Grande Villa and two other Health Care Providers by the FCC COVID-19 Telehealth Program, using telecommunication technology to reduce patients’ unnecessary risk of exposure to infectious disease and other dangers related to leaving the facility during recovery.

“For any telehealth solution to be successful in supporting senior living communities and nursing care facilities, it needs to give clinicians the tools capable of painting a clear clinical picture, but more critically, the ability for a nurse and provider to have a discussion,“ according to mTelehealth CEO Marc Poulshock. “Nonagon’s technology is nine steps ahead of the telehealth world by creating limitless access between patients, caretakers, and healthcare organizations.”

Vista Grande Villa is a 318-unit non-profit senior living community offering independent living, assisted living, memory care, and skilled nursing care.

“Since 1972, Vista Grande Villa has been committed to providing the best senior living experience in Jackson, Michigan and we are continuing that legacy by integrating Nonagon’s world-class telehealth services into our already successful health care,” said Vista Grande Villa Executive Director Chelsea Eisele. “Going forward, Vista Grande Villa’s skilled nursing center will be able to connect, consult, and access a more accurate level of diagnoses from physicians, as if they are on site. This will complement our existing on-site physician visits.”

“When Kauhale Healthcare began management of Vista Grande Villa in March 2022, we committed to bringing the best technology available to the campus and we believe that the Nonagon platform is just that, the best,” said Jim Palculict, COO of Kauhale Healthcare. “We looked at a number of options to telecommunicate with physicians and the one that stuck out is Nonagon because it provides so much more than a HIPAA-compliant video chat, it actually facilitates an intimate, informative virtual exam, and it is surprisingly cost-effective considering all that it does.”

“We are happy to serve the Vista Grande Villa community with our platform that caters to the needs of seniors as a multi-functional, cost-efficient, and accurate solution that can be carried in the palm of the hand while being versatile and adjustable to any type of organization,” according to Nonagon’s CEO Alon Natanson, “The minds behind this platform built it to benefit patients from infants to senior citizens, physicians of various specializations, and healthcare organizations — no matter how large or small. Nonagon is an all-in-one solution for all.”

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. Our Remote Health Monitoring System, Powered by aTouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. Furthermore, the innovative, cutting-edge, Nonagon N9 device and platform powers our virtual exam creating limitless access between healthcare organizations and their patients by bringing the clinician “into the room” with the patient like no other telehealth solution. We connect patients with their families and care providers through our easy-to-use, affordable, telehealth devices and platforms. For more information, visit their website: https://mtelehealth.com, Facebook, LinkedIn, and Twitter.

About Nonagon

Nonagon is a fast-growing medical device company, with offices based in Israel (HQ) and the United States. Nonagon seeks to make remote digital medicine clinically reliable and accessible to the community in the fields of family, chronic, and pediatric and is pursuing that by introducing new digital enhancements and creating new opportunities for better patient care. For more information, visit http://www.nonagon-care.com.

About Vista Grande Villa

Founded in 1972, Vista Grande Villa has been providing residential and care services to seniors in the Jackson region for more than 50 years. With its new management under Kauhale Healthcare, Vista Grande Villa ensures that the senior community will experience quality services and care while embracing individual choice and independence. For more information, visit: https://vistagrandevilla.com.

About Kauhale Healthcare Management
Founded in 2021, Kauhale Healthcare Management (kauhalehealth.com) is a Midwest-based firm led by five principals with a combined 130 years of experience in senior living/integrated post-acute care operations, acquisitions, operational transfers, and development. Their team has experience across 20 U.S. states, including management responsibilities for more than 300 stand-alone Independent Living (IL), Assisted Living (AL), Memory Care (MC), Skilled Nursing Facility (SNF), and Continuing Care Retirement Community (CCRC) properties.

The post mTelehealth Partners with Nonagon to Launch Transformative Virtual Telehealth Technology appeared first on mTelehealth.

Following an award grant from the Federal Communications Commission (FCC) COVID-19 Telehealth Program, Vista Grande Villa engages mTelehealth to integrate Nonagon’s state-of-the-art technology to expand its capacity to triage and diagnose patients on-site 24/7.

JACKSON, MICHIGAN – With the mission to strengthen its healthcare services for patients and residents, Vista Grande Villa officially announced the adoption of a game-changing digital telehealth platform, Nonagon, to provide its skilled nursing center with 24/7 access to patients’ health care providers (HCPs) whenever the need arises. Nonagon’s N9 hand-held device enables 9 medical-grade exams to be captured and shared with HCPs, bolstered by Nonagon’s proprietary, HIPAA-compliant, and secure communication platform and database.

The FDA-cleared N9 device communicates with a laptop, tablet, or smartphone for clinical-grade remote examinations of the heart, lungs, abdomen, oxygen saturation (important for diagnosing COVID), ears, mouth/throat, skin, and body temperature. Nonagon automatically documents and shares exam results (via photo, audio, video, or text-based message) to physicians which can help in improving health outcomes, reducing visits to the Emergency Room and reducing readmissions.

The integration of Nonagon into Vista Grande Villa’s skilled nursing center’s infrastructure, provided by mTelehealth, comes as part of a grant awarded to Vista Grande Villa and two other Health Care Providers by the FCC COVID-19 Telehealth Program, using telecommunication technology to reduce patients’ unnecessary risk of exposure to infectious disease and other dangers related to leaving the facility during recovery.

“For any telehealth solution to be successful in supporting senior living communities and nursing care facilities, it needs to give clinicians the tools capable of painting a clear clinical picture, but more critically, the ability for a nurse and provider to have a discussion, “according to mTelehealth CEO Marc Poulshock. “Nonagon’s technology is nine steps ahead of the telehealth world by creating limitless access between patients, caretakers, and healthcare organizations.”

Vista Grande Villa is a 318-unit non-profit senior living community offering independent living, assisted living, memory care, and skilled nursing care.

“Since 1972, Vista Grande Villa has been committed to providing the best senior living experience in Jackson, Michigan and we are continuing that legacy by integrating Nonagon’s world-class telehealth services into our already successful health care,” said Vista Grande Villa Executive Director Chelsea Eisele. “Going forward, Vista Grande Villa’s skilled nursing center will be able to connect, consult, and access a more accurate level of diagnoses from physicians, as if they are on site. This will complement our existing on-site physician visits.”

“When Kauhale Healthcare began management of Vista Grande Villa in March 2022, we committed to bringing the best technology available to the campus and we believe that the Nonagon platform is just that, the best,” said Jim Palculict, COO of Kauhale Healthcare. “We looked at a number of options to telecommunicate with physicians and the one that stuck out is Nonagon because it provides so much more than a HIPAA-compliant video chat, it actually facilitates an intimate, informative virtual exam, and it is surprisingly cost-effective considering all that it does.”

“We are happy to serve the Vista Grande Villa community with our platform that caters to the needs of seniors as a multi-functional, cost-efficient, and accurate solution that can be carried in the palm of the hand while being versatile and adjustable to any type of organization,” according to Nonagon’s CEO Alon Natanson, “The minds behind this platform built it to benefit patients from infants to senior citizens, physicians of various specializations, and healthcare organizations — no matter how large or small. Nonagon is an all-in-one solution for all.”

About Vista Grande Villa

Founded in 1972, Vista Grande Villa has been providing residential and care services to seniors in the Jackson region for more than 50 years. With its new management under Kauhale Healthcare, Vista Grande Villa ensures that the senior community will experience quality services and care while embracing individual choice and independence. For more information, visit: https://vistagrandevilla.com.

About Kauhale Healthcare Management
Founded in 2021, Kauhale Healthcare Management (kauhalehealth.com) is a Midwest-based firm led by five principals with a combined 130 years of experience in senior living/integrated post-acute care operations, acquisitions, operational transfers, and development. Their team has experience across 20 U.S. states, including management responsibilities for more than 300 stand-alone Independent Living (IL), Assisted Living (AL), Memory Care (MC), Skilled Nursing Facility (SNF), and Continuing Care Retirement Community (CCRC) properties.

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. Their Remote Health Monitoring System, Powered by aTouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. Furthermore, the innovative, cutting-edge, Nonagon N9 device and platform powers their virtual exam creating limitless access between healthcare organizations and their patients by bringing the clinician “into the room” with the patient like no other telehealth solution. Their connect patients with their families and care providers through their easy-to-use, affordable, telehealth devices and platforms. For more information, visit their website: https://mtelehealth.com, Facebook, LinkedIn, and Twitter.

About Nonagon

Nonagon is a fast-growing medical device company, with offices based in Israel (HQ) and the United States. Nonagon seeks to make remote digital medicine clinically reliable and accessible to the community in the fields of family, chronic, and pediatric and is pursuing that by introducing new digital enhancements and creating new opportunities for better patient care. For more information, visit www.nonagon-care.com.

Contact:                                                                       

Chelsea Eisele

Executive Director Vista Grande Villa

517.787.0222

The post Vista Grande Villa Levels Up Senior Care with Transformative Virtual Technology appeared first on mTelehealth.

NEWS PROVIDED BY Aetonix Systems 

Jun 23, 2022, 10:07 ET

OTTAWA, ON, June 23, 2022 /CNW/ – Aetonix Systems, the leading platform for virtual care and remote patient management has been selected by the Brant-Brantford Paramedic Services to enhance their community care programs. Over the last five years the aTouchAway® platform has proven to decrease ER usage while improving the health of patients in their own homes. The platform unitizes customized care pathways to combine a series on vitals collections (blood pressure, weight and oxygen saturation levels) with assessment questionnaires and educational materials. The platform has been specifically designed to cater to a senior population that might otherwise find challenges with technology.

“We are happy to work with Aetonix and look forward to enhancing care for the community we serve” said Glen Cunnane, Deputy Chief, Community Paramedicine, Brant/Brantford Paramedic Services.

This selection adds to the ever growing list of regional paramedics that have chosen the Aetonix platform as they look to enhance their community care offerings.

“We are delighted to work with Brant/Brantford paramedics on their excellent initiatives to optimize the care they offer” said Michel Paquet, CEO, Aetonix Systems Inc. “Paramedics are often the frontline of healthcare and being able to include them in our program that works with many of the hospitals/service providers in the region, is an excellent enhancement of service for the entire community”

About Aetonix: 

Aetonix is changing lives daily with its virtual care platform, aTouchAway®, which provides telehealth, care pathways and remote patient management to optimize connected health. Its community care platform is revolutionizing the way families, healthcare professionals and patients receive care. Over 250 hospitals and tens of thousands of patients use Aetonix globally. 

SOURCE Aetonix Systems

The post Brant-Brantford Paramedic Services select Aetonix Systems for their enhanced community care and remote home monitoring solution appeared first on mTelehealth.

OTTAWA, ON, June 2, 2022 /CNW/ – Aetonix Systems, the leading platform for virtual care and remote patient management, announced today that it has completed its SOC2 Type 2 audit of the aTouchAway™ System. SOC2 Type 2 indicates confidence from auditors that controls are being applied consistently and on an ongoing basis to all aspects of its business with a commitment to maintaining stringent and effective operation controls and processes for the security of its customer services and systems. The independent audit of Aetonix Systems was conducted by Richter LLP, one of the largest and most recognized independent consulting firms in Canada.

“Ensuring data security and confidentiality for our clients is of highest priority” said Michel Paquet, CEO at Aetonix Systems. “With our SOC2 Type 2 certification, we can continue to demonstrate to our customers our commitment to the highest level of security practices, often surpassing the exacting standards of the various national hospital and healthcare organizations we serve.”

SOC2 Type 2 audit consists of a rigorous examination by an independent accounting and auditing firm of the Aetonix Systems internal control policies, practices, procedures, and operations over a period of time.

“At Aetonix Systems, we work with many of the world’s leading healthcare providers to enable virtual care and remote patient management, an area that continues to accelerate following the pandemic. Data security and confidentiality has always underpinned everything we do and attaining SOC2 Type 2 certification formally recognizes this achievement,” said Michel Paquet.

About Aetonix: 

Aetonix is changing lives daily with its virtual care platform, aTouchAway®, which provides telehealth, care pathways and remote patient management to optimize connected health. Its face-to-face communication platform is revolutionizing the way families, healthcare professionals and patients receive care. Over 250 hospitals and tens of thousands of patients use Aetonix globally.

SOURCE Aetonix Systems

The post Aetonix Systems completes SOC2 Type 2 audit affirming its commitment to security and compliance appeared first on mTelehealth.

• Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing and pilot programs, which are considered the first steps towards seeking reimbursement for the device
• mTelehealth placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021
• The initiative by mTelehealth is expected to educate senior medical decision makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions
• Respiri is up 6.12 per cent, trading at 5.2 cents at 11:30 am AEDT

eHealth company, Respiri (RSH) has secured a second order for Wheezo from mTelehealth.

Developed in Australia, the Wheezo device analyses breath sounds for wheeze to assist patients with managing their asthma by tracking symptoms, triggers and medication use.

Respiri has teamed up with mTelehealth to provide customers with the Wheezo device for evaluation, testing, and pilot programs, which are considered the first steps towards seeking reimbursement for the device.

To do so, mTelehealth has placed a second order for additional Wheezo devices, representing revenues of around US$24,000 (around A$33,600) on top of the US$150,000 (A$210,000) order received in December 2021.

The initiative by mTelehealth is expected to educate senior medical decision-makers on the benefits of Wheezo, which is hoped to increase adoption of the device by mTelehealth customers and result in monthly subscriptions.

The devices are set to be air freighted immediately to key decision-makers within mTelehealth’s targeted customer base. This will enable a critical review, testing and evaluation required to expedite the piloting of Wheezo.

Respiri says these are considered the first and most difficult steps in seeking to secure reimbursement for Wheezo RPM services and inclusion of Wheezo in management protocols.

Over 600 customers have been targeted, with many of them already requesting Wheezo devices.

“Our partnership with mTelehealth has developed quickly with mTelehealth and the progress they have made with customers in only two months of customer engagement has exceeded all our expectations,” said CEO and Managing Director of Respiri, Marjan Mikel.

“This is a key step in seeking to get reimbursed Wheezo devices into the hands of patients that need it.”

Respiri was up 6.12 percent, trading at 5.2 cents at 11:30 am AEDT.

The post Respiri (RSH) secures second order from mTeleHealth appeared first on mTelehealth.

• mTelehealth to provide paying customers with devices for evaluation, testing and pilot programs, the first steps in seeking to secure reimbursement for wheezo®.

• Targeted senior medical decision makers from over 600 of mTelehealth target customers will be provided with wheezo® devices to allow for internal review, testing and pilot programs.

• The institutions targeted are Health Management Organisations (HMOs/Payors) and Health System with 1,000+ total beds and a minimum $1B in revenue that fund the delivery of reimbursed Remote Patient Monitoring (RPM), Telehealth and Chronic Care Management (CCM) to patients across the USA.

• These customers provide health insurance and care to 128 million Americans across the entire country which equates to about 19 million asthma and Chronic Obstructive Pulmonary Disorder (COPD) patients.

• mTelehealth is a premier provider of RPM services based in Florida

Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is pleased to announce that it has been working with our first partner mTelehealth to undertake action to convert the high levels of interests expressed in the wheezo® RPM solution. As a result, mTelehealth has placed a second order for additional wheezo® devices representing revenues of approximately US$24k on top of the US$150K order received on 23rd December 2021 as part of the signed agreement with mTelehealth as announced to ASX1. This additional order is not considered to be of a material financial nature to the Company. However, this strategic initiative by mTelehealth is expected to educate senior medical decision makers on the benefits of wheezo®, which in turn may result in increased adoption of the device by mTeleheath customers and associated monthly subscriptions, although an estimate of this potential revenue to Respiri cannot be reliably estimated, given future sales are subject to internal review, testing and pilot study outcomes.

Devices will be immediately air freighted and will be provided by mTelehealth to key decision-makers within their targeted customers base to allow for the critical review, testing and evaluation required to expedite the piloting of wheezo® which are the first and most difficult steps in seeking to secure reimbursement for wheezo® RPM services and inclusion of wheezo® in management protocols.

The over 600 customers have been targeted with many of them already requesting wheezo® devices following negotiations already had. The customers provide health insurance cover and healthcare delivery for approximately 128 million Americans across the country and roughly 19 million with asthma and COPD suffer based on local
epidemiology. These customers are broad from progressive smaller payor groups typically insuring 500,000 lives to large premier organizations insuring upwards of 4 million lives and all HMO types have expressed interest in evaluating the wheezo® RPM solution the first critical step to reimbursement approval.

CEO and Managing Director of Respiri, Mr. Marjan Mikel said “Our partnership with mTelehealth has developed quickly with mTelehealth and the progress they have made with customers in only 2 months of customer engagement has exceeded all our expectations. This mTelehealth funded initiative to engage with decision-makers and expedite the payor reimbursement approval process speaks volumes for the relationship Marc and his team have developed over 11 years of business. This is a key step in seeking to get reimbursed wheezo® devices into the hands of patients that need it.”

President and CEO of mTelehealth, Mr. Marc Poulshock said “We have seen an unprecedented positive response to our customer engagement activities to wheezo® and this acted as a catalyst for our investment in accelerating wheezo® evaluation with our customers. Things normally take time to change in the US health market but these
rules seem to not apply to wheezo® which we are pleased about.”

RPM is the use of digital technologies deployed in the collection and analysis of patient physiologic data that are used to develop and manage a treatment plan related to a chronic and/or acute health illness or condition. RPM systems improve patient health and device compliance, which leads to a reduction in hospital admissions and reduced healthcare costs. In parallel, RPM generates new revenue streams for healthcare providers while improving patient care and associated medical information outside the clinic for evaluation and management purposes.

The overall RPM market is expected to show annual growth exceeding 30% to 2026 to US$85 billion, driven by the increase in the occurrence of chronic diseases (including asthma), demand for wireless and portable systems, the presence of sophisticated reimbursement structures, and a move to more cost-effective medical expenditure.

For further information, investors and media please contact:
Mr. Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr. Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 4 February 2022 has been authorized for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri’s innovative technology, comprises an eHealth app combined with a simple, easy to use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians and other health care professionals.

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®

Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use, and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link https://wheezo.com

wheezo® is a registered trademark of Respiri Limited.

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, United States, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. mTelehealth’s Remote Health Monitoring System, Powered by a TouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. The company connect patients with their families and care providers through an easy-to-use, affordable, remote health monitoring kit. For more information about mTelehealth, please visit our website: https://mtelehealth.com.

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri current expectations, estimates, and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavor of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

The post Respiri secures a second order from United States Remote Patient Monitoring partner mTelehealth appeared first on mTelehealth.

ASX ANNOUNCEMENT
23 December 2021

Respiri enters its first 5 year Remote Patient Monitoring (RPM) Distribution/Marketing Agreement in the United States with mTelehealth, LLC
Highlights:
• Five-year, Non-Exclusive Distribution and Marketing Agreement signed with mTelehealth in the key US
market
• mTelehealth is a premier provider of RPM services based in Florida
• First key distribution and marketing agreement signed in the US market
• Initial US$150,000 order, with minimum forecast sales of US$1 million over the life of the agreement by mTelehealth
• Physicians will be able to claim RPM CPT reimbursement for wheezo® and Respiri will share these monthly recurring revenues in addition to the devices sales
• Further third party agreements anticipated as Respiri builds out US RPM strategy for wheezo®

Respiri Limited (ASX:RSH)(“Respiri” or the “Company”), an eHealth SaaS Company supporting respiratory health management is excited to announce its first non-exclusive distribution/marketing partnership with Remote Patient Monitoring (RPM) and chronic care provider mTelehealth LLC, effective immediately. Under the terms of the Agreement, mTelehealth has placed a significant initial order for wheezo® devices and services, totalling USD$150,000 in December 2021 for delivery in January 2022 and is contracted to . Either party can terminate with 30 days’ notice if there has been a material breach of the Agreement. This Agreement is material, as the Company currently has no US sales for wheezo®. mTelehealth has forecast a minimum of US$1 million in wheezo® device sales over the five years of the Agreement (forecast only) with a contracted minimum quarterly commitment of 1,000
wheezo® units.

In addition to these initial device sales, Respiri and mTelehealth will share the Product as a Service (PaaS) monthly fees that will be charged to physicians and other Healthcare Professionals claiming RPM and other CPT reimbursement codes.

mTelehealth is a well-respected and known provider of complete turnkey RPM and associated services to physicians and relevant healthcare delivery organisations for over 11 years and is domiciled in Florida, US. mTelehealth’s US footprint is broad and includes the Departments of Health and their County affiliates, payor Health Maintenance Organisations (HMOs), hospitals, Universities, Medical Centres, along with other RPM corporations and institutions. RPM is the use of digital technologies deployed in the collection and analysis of patient physiologic data that are used to develop and manage a treatment plan related to a chronic and/or acute health illness or condition. RPM systems improve patient health and device compliance, which leads to a reduction in hospital admissions and reduced healthcare costs. In parallel, RPM generates new revenue streams for healthcare providers while improving patient care and associated medical information outside the clinic for evaluation and management purposes. In the US, the physician and relevant healthcare physicians are reimbursed directly for providing medical devices to
patients allowing them to provide Remote Patient Monitoring services, which are reimbursed by HMOs and Medicare. Organisations like mTelehealth have built relationships with physicians and relevant medical and reimbursement institutions to deliver devices and services that enable the physician to provide said RPM service enabling them to claim the reimbursement. Respiri has developed a US commercialisation strategy around forging strategic partnerships with such RPM service providers with these existing relationships. The US market is large and fragmented and there is no single company providing national coverage, hence Respiri’s strategy is to execute further agreements to gain broader coverage in the market. Respiri is delighted to have executed an agreement with mTelehealth, as a premier and first partner of the Company.

The overall RPM market is expected to show annual growth exceeding 30% to 2026 to US$85 billion, driven by the increase in the occurrence of chronic diseases (including asthma), demand for wireless and portable systems, the presence of sophisticated reimbursement structures, and a move to more cost effective medical expenditure.1

CEO and Managing Director of Respiri, Mr Marjan Mikel said “We are particularly excited about our partnership with mTelehealth, a trusted RPM partner to many healthcare delivery organisations and physicians across the United States. Marc and his team very quickly understood what patient benefits wheezo® could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri. This agreement demonstrates that we are executing on our US strategy.”

President and CEO of mTelehealth, Mr Marc Poulshock said “We have a long pedigree in providing our customers across the United States with chronic care and remote patient monitoring turnkey solutions and we could see the health benefits that wheezo® could provide patients with asthma where very little, in the form of RPM solutions are available today. Part of our wheezo® due diligence was to discuss the device with physicians, HMOs and local Department of Health authorities and the responses were very positive. This was again reflected in the high level of inquiry that our initial marketing campaign waves generated from very large HMOs to county health departments and we are very confident with our 5 year forecasts for wheezo® sales. There is definitely a need for wheezo® in the US and we are pleased to have partnered with Respiri in this large and growing market.”

The Company is in active discussions with a number of additional RPM/chronic care providers, which should be finalised progressively during 2022.

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873

E: marjan@respiri.co

Mr Nicholas Smedley

Executive Chairman

Respiri Limited

P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement dated 23 December 2021 has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited

Respiri is an e-Health SaaS company supporting respiratory health management. Its world-first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. wheezo®, Respiri’s innovative technology, comprises an eHealth app combined with a simple, easy-to-use, handheld device. wheezo® is the first smart device to help improve asthma management by monitoring wheeze and documenting symptoms, signs, triggers, weather conditions and medication use. The asthma management platform also facilitates the sharing of data with caregivers, physicians, and other health care professionals.

1 https://www.businesswire.com/news/home/20210720005704/en/85-Bn-Remote-Patient-Monitoring-Market—Global-Forecasts-from-2021-to-2026—
ResearchAndMarkets.com

Respiri’s mission is to help improve quality of life for hundreds of millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. Respiri Limited’s operations are based in Melbourne, Australia.

For additional information about Respiri and its products, please visit www.respiri.co

About wheezo®
Developed in Australia, with the support of respiratory specialists and other healthcare professionals, the innovative wheezo® device analyses breath sounds for wheeze, and the eHealth App assists patients with managing their asthma by tracking symptoms, triggers, medication use and geo-specific weather conditions. The platform has been designed to extend asthma management beyond the clinic and make it easy to share information with doctors and make appropriate adjustments to asthma action plans. Better active management may lead to better outcomes and improved quality of life for the asthma patient.

For further information about wheezo®, follow the online link https://wheezo.com

wheezo® is a registered trademark of Respiri Limited.

About mTelehealth

mTelehealth, LLC, founded in 2010 and based in Delray Beach, FL, United States, is a premier provider of Remote Patient Monitoring (RPM), Remote Therapeutic Monitoring (RTM), Telemedicine, Chronic Care Management (CCM), Virtual Exam, Video Visit, and related Telehealth solutions. mTelehealth’s Remote Health Monitoring System, Powered by a TouchAway™, provides a complete solution to remotely collect, store, and report timely and accurate health information anywhere. The company connect patients with their families and care providers through an easy-to-use, affordable, remote health monitoring kit. For more information about mTelehealth, please visit our website: https://mtelehealth.com.

Forward Looking Statements

Certain statements made in this announcement are forward-looking statements. These forward looking statements are not historical facts but rather are based on Respiri current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward looking statements, which reflect the view of Respiri only as of the date of this release. The forward looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

The post Respiri enters its first 5 year Remote Patient Monitoring (RPM) Distribution/Marketing Agreement in the United States with mTelehealth, LLC appeared first on mTelehealth.

The e-health company’s shares closed in the green today on news of a new partnership

Published December 23, 4:39pm AEDT

The Respiri Ltd (ASX: RSH) share price leapt 14% to 6.5 cents in early trading this morning. This came following the announcement of a distribution and marketing deal with a United States healthcare company.

At the closing bell, Respiri shares had wiggled back down to 5.9 cents apiece, a 3.5% increase from yesterday’s closing price.

Respiri’s telehealth deal

At its core, Respiri is focused on bringing simple respiratory solutions to those living with asthma.

Its primary product, wheezo, assists in the tracking and management of asthmatic symptoms. It also has the ability to share relevant information with doctors and caregivers.

The deal driving the Respiri share price today combines the efforts of US-based remote patient monitoring (RPM) provider mTelehealth, LLC with Respiri.

The partnership entails an initial request from mTelehealth for USD$150,000 (A$208,000) worth of wheezo devices and services to be delivered as early as next month.

Up until now, wheezo products had not been sold in the US.

Respiri also predicts the RPM market will grow by more than 30% by 2026, up to US$85 billion, due to the increase in asthma and chronic diseases.

Therefore, mTelehealth has predicted US$1 million in wheezo sales over the next five years and has agreed to obtain a minimum of 1,000 units every quarter.

This marks the first deal of its kind signed for Respiri.

Respiri CEO pleased with the partnership

Commenting on the news fuelling the Respiri share price today, CEO and managing director Marjan Mikel said:

We are particularly excited about our partnership with mTelehealth, a trusted RPM partner to many healthcare delivery organisations and physicians across the United States.

Marc [Poulshock, president and CEO of mTelehealth] and his team very quickly understood what patient benefits wheezo could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri.

Poulshock said there was “definitely a need for wheezo in the US” and the company was pleased to have entered the partnership.

Respiri share price snapshot

The Respiri share price has seen a year in red, declining by around 55%.

The company has a market capitalisation of $41.2 million based on its current share price and over 720 million shares issued.

The post Here’s why the Respiri (ASX:RSH) share price jumped 14% today appeared first on mTelehealth.

Markets Reporter

jessica.defreitas@themarketherald.com.au

23 December 2021 14:54 (AEDT)

Respiri (RSH) has entered a non-exclusive distribution and marketing partnership with remote patient monitoring (RPM) and chronic care provider, mTelehealth.

Under the deal, the US-based healthcare company will place an order for Respiri’s wheezo devices and services.

Importantly for Respiri, this marks its first key distribution and marketing deal in the US market.

The wheezo device analyses breath sounds and the eHealth app helps patients with managing their asthma by tracking symptoms, triggers, medicine use and weather conditions.

wheezo is available in pharmacies across Australia and received the tick of approval from the US Food and Drug Administration earlier this year.

Respiri has been focused on commercialising its product in the US market and forming partnerships with Remote Patient Monitoring (RPM) service providers and was pleased to be signing the agreement.

Respiri and mTelehealth will share the Product as a Service (PaaS) monthly fees that will be charged to physicians and other Healthcare Professionals claiming RPM and other Current Procedural Terminology (CPT) reimbursement codes.

Respiri CEO and Managing Director Marjan Mikel is excited about the partnership, praising mTelehealth CEO Marc Poulshock and his team.

“Marc and his team very quickly understood what patient benefits wheezo could provide and imparted invaluable local knowhow to help us better tune our US launch strategy and leverage the existing RPM CPT reimbursement codes available to Respiri. This agreement demonstrates that we are executing on our US strategy.”

The initial order is valued at US$150,000 (A$208,087) however mTelehealth has forecast at least US$1 million (A$1.4 million) in wheezo device sales over the five year term of the agreement. The deal has a contracted minimum quarterly commitments of 1000 wheezo units.

In addition to the initial device sales, Respiri and mTelehealth will share the product-as-a-service monthly fees that will be charged to physicians and other health professionals who claim RPM and other CPT reimbursement codes.

The devices are expected to be delivered in January.

Company shares were up 3.51 per cent and trading at 5.9 cents at 2:11 pm AEDT.

The post Respiri (ASX:RSH) enters US distribution deal with mTelehealth appeared first on mTelehealth.